Fool.com
The World's Greatest Investing Community
Results 1 - 10 of 609 : 1 2 3 4 5 6 7 8 9 Next
Our Final Offer (Maybe)! That's a FACT!
Biogen ups its bid for Facet.
Merck Makes a Mark on Good Cholesterol
Can't profit from fighting bad lipoproteins? Start boosting the good ones.
Drug companies shape up, and it shows in their margins.
Eli Lilly adds another approval onto Cymbalta.
The Real Problem With the Public Health-Care Plan
It's the morphing part that should scare you.
3 Ridiculously Cheap, High-Quality Companies
Come and get 'em while they're hot.
A Mostly Meaningless FDA Approval
After an accelerated approval, the positive effects of a full approval are minimal.
Biotech Bargains for Your Portfolio
It's Black Friday, after all.
7 of the Most Efficient Companies on the Planet
These companies can bring some of their efficiency to your portfolio.
A Big Upgrade for Amylin Pharmaceuticals
This bullish call comes from more than just one analyst.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK